Trial · NCT01039519
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Showing Clinical Benefit Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 | Ganetespib 200 mg/m^2 | 18.5 | percentage of participants | ||
| Percentage of Participants Showing an Objective Response Based on RECIST Version 1.0 | Ganetespib 200 mg/m^2 | 0 | percentage of participants | ||
| Kaplan-Meier Estimate of Progression Free Survival (PFS) | Ganetespib 200 mg/m^2 | 1.8 | 95% Confidence Interval 1.6 to 3.5 | months | |
| Kaplan-Meier Estimate of Overall Survival | Ganetespib 200 mg/m^2 | 10.3 | 95% Confidence Interval 5.8 to 13.6 | months | |
| Percentage of Participants Showing a Tumor Response During Cycle 1 in Selected Participants Measured by Positron Emission Tomography (PET) | Ganetespib 200 mg/m^2 | 66.7 | percentage of participants | ||
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >=1 AE | 27 | participants | |
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >=1 AE with severity grade >=3 | 15 | participants | |
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >= 1 SAE | 10 | participants | |
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >=1 AE leading to dose modification | 10 | participants | |
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >=1 AE leading to dose interruption | 1 | participants | |
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >=1 AE leading to study drug discontinuation | 3 | participants | |
| Count of Participants With Treatment-Emergent Adverse Events (AEs) | Ganetespib 200 mg/m^2 | >=1 AE with an outcome of death | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01039519/results